Novel Cancer Therapy: Pain Treatment Discovery (Lung, Anticancer)   Lung and Other Malignant Cancer Pain Biotherapeutics Biopharmaceuticals

Our Company

Management Team

John Reid, Managing Director, is a co-founder and seed investor in the Company.  John has successfully concentrated in the vital start-up activities of initial funding and venture capital procurement, information dissemination, and liaison with legal, financial, medical and scientific advisors in Ireland.  Having succeeded in procuring important licence and technology agreements a key role now is the shaping and implementation of a comprehensive business development plan, an important aspect of which will be the identification and selection of a suitably qualified and experienced CEO.

John has an MSc International Business Management from Trinity College, Dublin.

Celtic Biotech: Biopharmaceuticals and Biotherapeutics Drug Discovery Drug Discovery

Dr. Paul F. Reid, Chief Scientific Officer, is a co-founder and seed investor in the Company. Paul is a leading world expert in the therapeutic use of snake venom neurotoxins.  His collaborations with Prof. Zheng Hong Qin, Harvard University, have led to three new patent applications on behalf of the Company in relation to proprietary compounds and publication of a number of articles in peer reviewed international publications.  Paul is widely experienced in USA medical regulatory affairs and FDA protocols and has been CEO of several early-stage biotechnology companies in Florida.  Paul has extensive experience in drug production, new drug development, clinical trial design, and experimental design.

Paul has a Phd Neuro-biochemistry from Imperial College, London, and BA Microbiology from Trinity College, Dublin. 

Stephen Long is Financial Officer. Stephen has significant experience at management level in Strategic Planning and Implementation. His experience ranges from consultancy for young Irish Companies penetrating foreign markets to Regulatory Compliance for established Multinationals.  Stephen has operated at Director, Financial Controller and Finance Manager level in various heavily regulated industries and is recently appointed company secretary to Celtic Biotech.

Stephen is a Fellow Chartered Certified Accountant and also holds an MSc in International Business Management.


Scientific Board of Advisors

In addition to Dr. Reid, the Company has assembled a Scientific Board of Advisors retaining the consultative services and contributions of:

    Dr. Roscoe Moore, DVM, former Assistant United States Surgeon General and Rear Admiral USPHS (Ret). Dr Moore has focused over his career on the prevention, treatment and control of infectious diseases worldwide. He directed the Epidemiology program for the Howard University Comprehensive Cancer Center and held an oncology faculty appointment in its Medical College. Dr. Moore was also for an extended time the Senior Epidemiologist in the Office of the Director, National Institute for Occupational Health and Safety/CDC having a primary focus on "occupational exposures" and cancer outcomes. Dr Moore is Assistant Professor of Oncology at Howard U. Medical College and a member of the advisory board of directors for the Fogarty International Center/NIH.

    Prof. Zheng Hong Qin, Harvard and Suzhou Universities. Prof. Qin is a co-inventor on Celtic Biotech's first patent application and has conducted extensive pre-clinical research on behalf of the Company. His expert knowledge of venom neurotoxins has been a major asset to the Company and has been responsible for Celtic Biotech's peer reviewed published papers to date.

    Prof. John Crown, Senior Oncologist, St Vincent’s University Hospital, Dublin, and newly elected Senator, participated significantly in the development of the CB24 Phase Ib clinical trial protocol developed by the company. He is an international renowned Clinical Investigator and a founding member and ex-President of the All Ireland Clinical Oncology Research Group (ICORG).

    Dr. Dorothy Bray, Ph.D., CEO of Immunoclin Ltd. Dr. Bray is former head of HIV drug development for Glaxo Smithkline and is a specialist in clinical drug development and the coordination and conduct of clinical trials. She is a France/UK based CRO specialising in bespoke trials of novel and innovative drug therapies.

    Dr. Larry Raymond, Chief Science Officer of Receptopharm Inc., Florida. Dr. Raymond specialises in immunology and is an expert in the production of monoclonal antibodies and assay development. He has extensive experience in the development of medicinal therapies from snake venom neurotoxins.

    for more information

       CONTACT US    LINK RESOURCES    HOME PAGE
    Novel Cancer Therapy: Pain Treatment Discovery (Lung, Anticancer)
    Copyright © 2005 Celtic Biotech, Ltd.: Novel Cancer Therapy & Pain Treatment Drug Discovery
    Email Us   Top of Page